In general GLP-1 RA trials point to a strong effect on new persistent macroalbuminuria [22–24], but there is limited evidence of improvement on eGFR-based endpoints: sustained eGFR decline of 40–50% for dulaglutide [23], and a small reduction in eGFR decline with liraglutide and dulaglutude in participants with moderate-to-severe CKD. Here, GCG is linked to chronic kidney disease.